Drug Company Reprimanded for False Advertising

By: Radha McLean

Novo Nordisk Pharmaceuticals of Denmark violated federal regulations for inaccurately representing the type 2 drug Prandin (repaglinide) in promotional materials, according to the U.S. Food and Drug Administration (FDA).

In a May 1 statement, the FDA announced that the drug manufacturer understated the risks of Prandin and inflated its efficacy in advertising paraphernalia such as posters, sales aids and professional exhibits.

The FDA asked that Novo Nordisk immediately discontinue those materials and any others making such claims.

In an interview with Reuters Health, Novo Nordisk spokeswoman Susan Jackson denied that the company violated FDA regulations.

Comments

comments

Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.